Livmoniplimab + Budigalimab in patients w hepatocellular carcinoma

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

Disease Types: Liver

Available at: Wytheville, Salem, Roanoke, Alleghany, Blacksburg

A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment

For More Information:

https://clinicaltrials.gov/study/NCT06109272?term=Livmoniplimab%20in%20Combination%20with%20Budigalimab%20in%20Subjects%20with%20Locally%20Advanced%20or%20Metastatic%20Hepatocellular%20Carcinoma%20(HCC)%20Who%20Have%20Not%20Previously%20Received%20Systemic%20Treatment&rank=1